

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



創美·CH'MEI

**Charmacy Pharmaceutical Co., Ltd.**

**創美藥業股份有限公司**

*(A joint stock limited liability company incorporated in the People's Republic of China)*

**(Stock Code: 2289)**

## **PROFIT WARNING**

This announcement is made by Charmacy Pharmaceutical Co., Ltd. (the “**Company**”, together with its subsidiaries referred to as the “**Group**”) pursuant to Rule 13.09(2)(a) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the laws of Hong Kong).

The board of directors of the Company (the “**Board**”) wishes to inform the shareholders of the Company (the “**Shareholders**”) and potential investors that, based on a preliminary review of the management accounts of the Group for the year ended 31 December 2023 (the “**Reporting Period**”) and the information currently available to the Board, the Group expects to record a decrease in net profit attributable to shareholders of the parent company by approximately 45% compared to that for the year ended 31 December 2022 (the “**Corresponding Period**”). The significant expected decrease is mainly attributable to the Company’s one-off after-tax gain of approximately RMB49 million from cash compensation for land resumption in the Corresponding Period, which was not available in the Reporting Period. On the other hand, the Group’s net profit after deducting non-recurring gains and losses is expected to increase by approximately 22% compared with that for the Corresponding Period. The anticipated increase in net profit after deducting non-recurring gains and losses is mainly because the Company adhered to the business positioning of non-tender market and the market strategy of “intensive engagement in Guangdong Province and extensive coverage across surrounding areas”, winning the recognition and support of more brand manufacturers, obtaining more distribution rights and project cooperation opportunities for advantageous products, and on the other hand, the Company’s product satisfaction rate and supply chain service have been recognised by customers, brand recognition has been further improved, and the main business has shown good business performance.

As the Company is still in the process of finalising the Group’s annual results for the Reporting Period, the final results of the Group may be subject to changes and may be different from the information disclosed in this announcement. The information contained in this announcement is only the preliminary assessment according to the management accounts of the Group and the information currently available to the Board, which have not been audited or reviewed by the Company’s auditors or the audit committee of the Board. Financial information and other details of the Group will be disclosed in the announcement of annual results of the Group for the Reporting Period which is expected to be announced in late March 2024.

**Shareholders and potential investors should exercise caution when dealing in the shares of the Company.**

By Order of the Board  
**Charmacy Pharmaceutical Co., Ltd.**

**Yan Jingbin**

*Chairman*

Shantou, the PRC, 15 March 2024

*As at the date of this announcement, the executive directors of the Company are Mr. Yao Chuanglong, Ms. Zheng Yuyan and Ms. Zhang Hanzi; the non-executive directors of the Company are Mr. Yan Jingbin, Ms. Fu Zheng and Mr. Xu Fei; and the independent non-executive directors of the Company are Mr. Wan Chi Wai Anthony, Mr. Li Hanguo and Mr. Guan Jian (also known as Guan Suzhe).*